ArticleClinical trials (London, England)2014
SMART designs in cancer research: Past, present, and future.
Article in Clinical trials (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Use of Sequential Multiple Assignment Randomized Trials (SMARTs) in oncology: systematic review of published studies.British journal of cancer · 2023Pooled it
- Sequential multiple assignment randomized trial studies should report all key components: a systematic review.Journal of clinical epidemiology · 2022Pooled it
- Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions.PharmacoEconomics · 2021Pooled it
- Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Nature medicine · 2024Trial
- Multiple Pharmacotherapy Adaptations for Smoking Cessation Based on Treatment Response in Black Adults Who Smoke: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Optimal allocation to treatments in a sequential multiple assignment randomized trial.Statistical methods in medical research · 2021Trial
- Comparative inhibitory effects of zeolite, sepiolite, and kaolinite on A549 lung cancer cells.PloS one · 2026Article
- Moving toward response-adapted trials in oncology.Nature medicine · 2024Article
- A generalized logrank-type test for comparison of treatment regimes in sequential multiple assignment randomized trials.Biometrics · 2024Article
- Adaptive randomization methods for sequential multiple assignment randomized trials (smarts) via thompson sampling.Biometrics · 2024Article
- Understanding heterogeneity of responses to, and optimizing clinical efficacy of, exercise training in older adults: NIH NIA Workshop summary.GeroScience · 2023Review
- Associations of disordered eating with the intestinal microbiota and short-chain fatty acids among young adults with type 1 diabetes.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2023Article
- The Intestinal Microbiota and Short-Chain Fatty Acids in Association with Advanced Metrics of Glycemia and Adiposity Among Young Adults with Type 1 Diabetes and Overweight or Obesity.Current developments in nutrition · 2022Article
- Design of the Advancing Care for Type 1 Diabetes and Obesity Network energy metabolism and sequential multiple assignment randomized trial nutrition pilot studies: An integrated approach to develop weight management solutions for individuals with type 1 diabetes.Contemporary clinical trials · 2022Article
- Morpholine substituted quinazoline derivatives as anticancer agents against MCF-7, A549 and SHSY-5Y cancer cell lines and mechanistic studies.RSC medicinal chemistry · 2022Article
- Bayesian set of best dynamic treatment regimes: Construction and sample size calculation for SMARTs with binary outcomes.Statistics in medicine · 2022Article
- Randomized and non-randomized designs for causal inference with longitudinal data in rare disorders.Orphanet journal of rare diseases · 2021Review
- Ascertaining properties of weighting in the estimation of optimal treatment regimes under monotone missingness.Statistics in medicine · 2020Article
- Sample size considerations for comparing dynamic treatment regimens in a sequential multiple-assignment randomized trial with a continuous longitudinal outcome.Statistical methods in medical research · 2020Review
- The use of PROMs and shared decision-making in medical encounters with patients: An opportunity to deliver value-based health care to patients.Journal of evaluation in clinical practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundCancer affects millions of people worldwide each year. Patients require sequences of treatment based on their response to previous treatments to combat cancer and fight metastases. Physicians provide treatment based on clinical characteristics, changing over time. Guidelines for these individualized sequences of treatments are known as dynamic treatment regimens (DTRs) where the initial treatment and subsequent modifications depend on the response to previous treatments, disease progression, and other patient characteristics or behaviors. To provide evidence-based DTRs, the Sequential Multiple Assignment Randomized Trial (SMART) has emerged over the past few decades. PURPOSE: To examine and learn from past SMARTs investigating cancer treatment options, to discuss potential limitations preventing the widespread use of SMARTs in cancer research, and to describe courses of action to increase the implementation of SMARTs and collaboration between statisticians and clinicians.
conclusionThere have been SMARTs investigating treatment questions in areas of cancer, but the novelty and perceived complexity has limited its use. By building bridges between statisticians and clinicians, clarifying research objectives, and furthering methods work, there should be an increase in SMARTs addressing relevant cancer treatment questions. Within any area of cancer, SMARTs develop DTRs that can guide treatment decisions over the disease history and improve patient outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.